Under the terms of the 10 year agreement, Akorn will be responsible for the development, manufacturing and supply of two new ophthalmic products.
Akorn estimates annual manufacturing revenue from this agreement of approximately $2-3 million. These two ophthalmic products are targeted for launch in mid-2009.
Arthur Przybyl, Akorn’s president and CEO, said: “This agreement reflects Akorn’s commitment to expanding our contract pharmaceutical manufacturing business unit.”